806 related articles for article (PubMed ID: 27696189)
1. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Mallat SG; Al Kattar S; Tanios BY; Jurjus A
Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
3. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
4. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
5. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
6. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
7. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
8. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Yang AY
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
Oh TR; Choi HS; Kim CS; Bae EH; Ma SK; Sung SA; Kim YS; Oh KH; Ahn C; Kim SW
Sci Rep; 2019 Apr; 9(1):6681. PubMed ID: 31040373
[TBL] [Abstract][Full Text] [Related]
10. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
11. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.
Kielstein JT; Pontremoli R; Burnier M
Curr Hypertens Rep; 2020 Oct; 22(12):102. PubMed ID: 33128170
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Hyperuricemia in Chronic Kidney Disease.
Ramirez-Sandoval JC; Madero M
Contrib Nephrol; 2018; 192():135-146. PubMed ID: 29393124
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
14. Challenges of conducting a trial of uric-acid-lowering therapy in CKD.
Badve SV; Brown F; Hawley CM; Johnson DW; Kanellis J; Rangan GK; Perkovic V
Nat Rev Nephrol; 2011 May; 7(5):295-300. PubMed ID: 21321568
[TBL] [Abstract][Full Text] [Related]
15. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Levy G; Shi JM; Cheetham TC; Rashid N
Perm J; 2018; 22():17-142. PubMed ID: 30201087
[TBL] [Abstract][Full Text] [Related]
16. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
[TBL] [Abstract][Full Text] [Related]
17. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
Kanji T; Gandhi M; Clase CM; Yang R
BMC Nephrol; 2015 Apr; 16():58. PubMed ID: 25928556
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
19. Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.
Mortada I
Curr Hypertens Rep; 2017 Sep; 19(9):69. PubMed ID: 28770533
[TBL] [Abstract][Full Text] [Related]
20. New insights into uric acid effects on the progression and prognosis of chronic kidney disease.
Filiopoulos V; Hadjiyannakos D; Vlassopoulos D
Ren Fail; 2012; 34(4):510-20. PubMed ID: 22260409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
